Research Focus Areas
Custom Synthesis of Metal/Porous Nanoparticles
Nanotoxicology
Biomedical Image Contrast Agents
Precision Nanoprobes
Molecular Nanotechnology
Custom Synthesis of Metal/Porous Nanoparticles
Standardized synthesis of Gold nanoparticles (nanoclusters, 5 nm, 10 nm, 16 nm) Silver nanoparticles (nanoclusters, 10 nm, 40 nm, 95 nm) Iron oxide nanoparticles (10 nm) Gadolinium oxide (5 nm, 10 nm) Hafnium oxide (5 nm, 10 nm) Microporous silica particles (15 nm, 50 nm, 100 nm, 400 nm) Other nanoparticles currently being optimized include …
Nanotoxicology
Nanotoxicity assessment is an integral part of designing biomedical probes. In vitro toxicity of nanoparticles is assessed using murine (L929) and human cell lines (HUVEC, RAW246.7). In vivo toxicity was assessed in zebrafish models, and in vivo biodistribution/blood pool kinetics was assessed in athymic and euthymic mouse models. Representative Publications …
Biomedical Image Contrast Agents
Scaled up the synthesis of nanoparticle contrast agents. I specialize in the synthesis of long emission lifetime, fluorescent and photoluminescent nanoparticles. This is achieved by modifying Au cores with fluorophore embedded shells or Au nanoclusters with tunable photoluminescence. Fluorescent silica particles with sizes ranging from 15 nm to 400 nm are also available. Such probes …
Precision Nanoprobes
Antibody-drug conjugates are emerging as a frontrunner in precision targeted therapeutics. However, this capability is still beyond the ability of most academic laboratories. The primary reason for this is the need to identify a precise binding site on the constant region of the antibody (Fc) for the drug molecule to be conjugated, while not affecting …
Molecular Nanotechnology
This is the current focus of my research. Utilizing anisotropic and hybrid nanoparticle architectures to introduce directionality in motion, precisely orienting targeting molecules and directed exertion of force by nanosystems. Anisotropic nanoparticles can be Janus hybrids or non-spherical nanoparticles and include rods, plates, prisms, and core-shells. This will lay the basis for nanomotors and nanomachines …
Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL)
Dr. Nallathamby presented on his abiotic biomimicking antibacterial Nanoparticles, and how they were successfully tested against A. baumannii BA1605 S.aureus USA300, P.aeruginosa FRD1, K. pneumoniae, C.striatum, E. faecalis, and S. pyogenes. We saw little to no evolution of resistance at doses above the MIC. Additionally, we observed what looks like inflammation-free wound healing in mouse and rat models. The wound size stabilizes as soon as the formulation is …
Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa
Congratulations to REUs Argerie Guevara (NURF’21), and Kevin Armknecht (NURF’23) and Carlie Kudary (#BIPH) on the prolonged antibacterial action formulation of standard antibiotics to tackle MRSA and P.aeruginosa. More to come this year. #AMR #GOIRISH https://doi.org/10.1093/milmed/usae079
NIH Funding Opportunities
- Notice of Question and Answer "Office Hours" with NIH Staff for the Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) Funding Opportunities RFA-DA-25-037, RFA-DA-25-038 September 19, 2024Notice NOT-DA-24-042 from the NIH Guide for Grants and Contracts
- Notice of Participation of the NIAAA in NOSI: Analysis of Existing Linked Datasets to Understand the Relationship between Housing Program Participation and Risk for Chronic Diseases and Other Conditions (R01-Clinical Trial Not Allowed). September 19, 2024Notice NOT-AA-24-009 from the NIH Guide for Grants and Contracts
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) September 18, 2024Funding Opportunity RFA-NS-25-023 from the NIH Guide for Grants and Contracts. This funding opportunity is part of a suite of NOFOs within the NIH HEAL Initiative to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal is to encourage initial translational efforts that will support a drug discovery program and […]
- Notice of Participation of the National Cancer Institute (NCI) in RFA-NS-24-041, "NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional). September 18, 2024Notice NOT-CA-24-108 from the NIH Guide for Grants and Contracts
- Findings of Research Misconduct September 18, 2024Notice NOT-OD-24-174 from the NIH Guide for Grants and Contracts
- Findings of Research Misconduct September 18, 2024Notice NOT-OD-24-173 from the NIH Guide for Grants and Contracts
- Notice of Pre-Application Technical Assistance Webinar for RFA-HS-24-004 for State-based Healthcare Extension Cooperatives to Accelerate Implementation of Actionable Knowledge into Practice (U19) September 17, 2024Notice NOT-HS-24-025 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): NIDDK T32 Medical Student Research Training Administrative Supplement September 17, 2024Notice NOT-DK-24-037 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Training Program in Application of Artificial Intelligence in Development of Treatment for Substance Use Disorders) September 17, 2024Notice NOT-DA-26-004 from the NIH Guide for Grants and Contracts
- U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional) September 17, 2024Funding Opportunity RFA-AI-24-023 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support research projects under Phase 3 of the U.S.-South Africa Program for Collaborative Biomedical Research. Research areas supported under this program include HIV/AIDS, HIV/AIDS co-morbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data […]
Recent Comments